These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 12904684)

  • 21. Losartan improves resistance artery lesions and prevents CTGF and TGF-beta production in mild hypertensive patients.
    Gómez-Garre D; Martín-Ventura JL; Granados R; Sancho T; Torres R; Ruano M; García-Puig J; Egido J
    Kidney Int; 2006 Apr; 69(7):1237-44. PubMed ID: 16482098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
    Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular and clinical response to angiotensin II receptor antagonist in kidney transplant patients with chronic allograft nephropathy.
    Mas VR; Alvarellos T; Maluf DG; Ferreira-Gonzalez A; Oliveros L; Maldonado RA; de Boccardo G
    Transpl Int; 2004 Oct; 17(9):540-4. PubMed ID: 15349718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease.
    Ecder T; Chapman AB; Brosnahan GM; Edelstein CL; Johnson AM; Schrier RW
    Am J Kidney Dis; 2000 Mar; 35(3):427-32. PubMed ID: 10692268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy.
    Holdaas H; Hartmann A; Berg KJ; Lund K; Fauchald P
    Nephrol Dial Transplant; 1998 Dec; 13(12):3096-102. PubMed ID: 9870472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation.
    Tylicki L; Rutkowski P; Renke M; Rutkowski B
    Am J Nephrol; 2002; 22(4):356-62. PubMed ID: 12169868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and effects on lipid metabolism of combination treatment with losartan + hydrochlorothiazide versus losartan + amlodipine: a 48-week prospective, multicenter, randomized, open-label trial.
    Nishiwaki M; Hosoai H; Ikewaki K; Ayaori M; Yamashita T; Shige H; Higashi K; Nashida Y; Shimizu S; Kijima F; Yokoyama M; Nakamura H;
    Clin Ther; 2013 Apr; 35(4):461-73. PubMed ID: 23490288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the efficacy and safety of fixed-dose amlodipine/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study.
    Hong BK; Park CG; Kim KS; Yoon MH; Yoon HJ; Yoon JH; Yang JY; Choi YJ; Cho SY
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):189-95. PubMed ID: 22462558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial.
    Scaglione R; Argano C; Corrao S; Di Chiara T; Licata A; Licata G
    J Hypertens; 2005 Mar; 23(3):657-64. PubMed ID: 15716710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. Canadian Cozaar Hyzaar Amlodipine Trial Study Group.
    Wilson TW; Lacourcière Y; Barnes CC
    CMAJ; 1998 Sep; 159(5):469-76. PubMed ID: 9757170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial.
    Webb NJ; Lam C; Shahinfar S; Strehlau J; Wells TG; Gleim GW; Le Bailly De Tilleghem C
    Nephrol Dial Transplant; 2011 Aug; 26(8):2521-6. PubMed ID: 21285125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease.
    Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Koide H; Ueda Y; Takeuchi M; Yamagishi S
    Clin Cardiol; 2011 Jun; 34(6):372-7. PubMed ID: 21432860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renin angiotensin system blockade ameliorates lead nephropathy.
    Ng HY; Tain YL; Lee YT; Hsu CY; Chiou TT; Huang PC; Lee CT
    Biochem Biophys Res Commun; 2013 Aug; 438(2):359-63. PubMed ID: 23896603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist therapy in hypertensive renal transplant recipients.
    Kim W; Lee S; Kang SK; Yu HC; Cho BH; Park SK
    Transplant Proc; 2002 Dec; 34(8):3223-4. PubMed ID: 12493427
    [No Abstract]   [Full Text] [Related]  

  • 35. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
    Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
    Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
    Zhu S; Liu Y; Wang L; Meng QH
    Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period.
    Formica RN; Friedman AL; Lorber MI; Smith JD; Eisen T; Bia MJ
    Nephrol Dial Transplant; 2006 May; 21(5):1389-94. PubMed ID: 16431893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Control of home blood pressure with an amlodipine- or losartan-based regimen and progression of carotid artery intima-media thickness in hypertensive patients: the HOSP substudy.
    Ohta Y; Kawano Y; Iwashima Y; Hayashi S; Yoshihara F; Matayoshi T; Takiuchi S; Kamide K; Nakamura S; Horio T
    Clin Exp Hypertens; 2013; 35(4):279-84. PubMed ID: 23530977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors.
    Aksnes TA; Reims HM; Guptha S; Moan A; Os I; Kjeldsen SE
    J Hum Hypertens; 2006 Nov; 20(11):860-6. PubMed ID: 16988754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction.
    Houlihan CA; Akdeniz A; Tsalamandris C; Cooper ME; Jerums G; Gilbert RE
    Diabetes Care; 2002 Jun; 25(6):1072-7. PubMed ID: 12032117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.